Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Delisting risk
confidence 92%
filed 2026-09-08
EX-99.1
The press release announces that Eupraxia's common shares "have commenced trading on the Nasdaq Global Select Market," representing a transfer from the Nasdaq Capital Market to Nasdaq's highest market tier. While this is technically an upgrade rather than a delisting risk, the delisting_risk category encompasses "transfer of listing" per the taxonomy. The move to the Global Select Market—Nasdaq's most stringent tier—is material to investors as it signals improved financial and liquidity standing and enhanced corporate governance compliance, affecting the registrant's market positioning and investor perception.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 90%
filed 2026-09-08
Item 3.03
La Rosa Holdings announced a 1-for-6 reverse stock split effective September 8, 2026, as a proactive measure to maintain compliance with Nasdaq's minimum bid price requirement and avoid a delisting deficiency notice. The company has not yet received a deficiency notice but is taking preemptive action to ensure continued listing compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-08
Item 3.01
Estrella Immunopharma received written notification from Nasdaq on September 1, 2026, that it failed to meet the minimum market value of listed securities (MVLS) requirement of $35,000,000 for 30 consecutive business days. The company has been granted a 180-day compliance period until March 1, 2027, to regain compliance, with the explicit warning that failure to do so will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-08
Item 3.01
Aterian received a formal notice from Nasdaq on September 2, 2026, that its common stock failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period ending March 1, 2027, to regain compliance, with failure to do so potentially resulting in delisting.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-08
The filing discloses that Galmed regained compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) after previously failing to maintain $1.00 per share for 30 consecutive trading days. The Company was notified of non-compliance on January 29, 2026, given a 180-day cure period (extended to 360 days total), and ultimately achieved compliance by September 3, 2026. This is a delisting-risk resolution: the Company faced potential delisting and has now cured the deficiency, bringing it back into full compliance with all applicable listing standards.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-08
EX-99.1
The exhibit is a shareholder letter from CEO Heng Hai Lim disclosing NYSE American delisting proceedings initiated in June 2026 following an SEC trading suspension in February 2026. The Panel affirmed the delisting determination on August 20, 2026, and the Company has appealed to the Committee for Review. This is a material delisting risk disclosure under Item 3.01 equivalent, as the Company's securities have been delisted from NYSE American and are now trading OTC, with the outcome of the appeal uncertain.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-08
EX-99.1
InterCure announced that it has regained compliance with Nasdaq's minimum bid price requirement after receiving a delisting notice on September 1, 2026. The company's shares had traded below $1.00 per share for 30 consecutive business days, triggering non-compliance in February 2026. Although the company ultimately regained compliance by September 8, 2026, the disclosure documents the delisting risk event and its resolution, which is material to investors assessing the registrant's continued listing status and market viability.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-08
Cosan has filed Form 25 with the SEC for voluntary delisting of its American Depositary Shares from the NYSE, effective September 18, 2026. The company will transition to Level I ADR trading on the OTC market. This is a material change in listing status that directly affects the registrant's U.S. capital market access and is a core delisting_risk disclosure.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-09-03
The filing discloses a 1-for-50 reverse share split approved by the Board on August 17, 2026, explicitly stated to be "intended to increase the market price per share of the Company's ordinary shares to allow the Company to maintain compliance with Nasdaq continued listing requirements." This is a material disclosure of delisting risk — the company is taking corrective action to avoid falling below Nasdaq's minimum bid price requirement, a clear signal of listing compliance jeopardy.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-09-03
Alpha Compute Corp announced a 1-for-50 reverse share split effective September 9, 2026, explicitly stating the split is "intended to increase the market price per share of the Company's ordinary shares to allow the Company to maintain compliance with Nasdaq continued listing requirements." This disclosure reveals the company faces delisting risk due to failure to satisfy Nasdaq's minimum bid price requirement, making this a material delisting-risk event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-03
Gulf Resources received a Nasdaq Extension Letter on September 1, 2026, granting additional time to regain compliance with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the quarter ended June 30, 2026. The filing explicitly states that if the Company fails to evidence compliance upon filing the delinquent Form 10-Q, "Staff will notify the Company that its securities will be subject to delisting." This is a classic delisting-risk disclosure under Item 3.01, with material consequences for continued trading on Nasdaq.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-09-03
EX-99.1
TNL Mediagene announced a 1-for-8 share consolidation explicitly "intended to increase the per-share trading price of the Company's ordinary shares to assist in regaining compliance with the Nasdaq minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market." The forward-looking statements section further references "the potential delisting of the Company's securities from Nasdaq," confirming that the registrant faces a material delisting risk that prompted this capital structure action.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-03
Item 3.01
The Company received a written notice from Nasdaq on September 1, 2026, stating it does not satisfy Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the period ended June 30, 2026. Although characterized as a "notification of deficiency, not of imminent delisting," this is a material delisting-risk disclosure under Item 3.01. The Company cured the deficiency by filing the Form 10-Q on September 1, 2026, and received written confirmation of compliance from Nasdaq on September 3, 2026, but the notice itself represents a failure to satisfy a continued listing standard.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-03
EX-99.1
The press release discloses that Nasdaq has granted DeFi Technologies an additional 180-day compliance period (until March 1, 2027) to regain compliance with the minimum bid price requirement of US$1.00 per share. The company's stock price fell below this threshold, triggering an initial compliance notice on March 5, 2026. The disclosure explicitly states "There can be no assurance that the Company will regain compliance within the additional compliance period or otherwise maintain compliance with Nasdaq's continued listing requirements," indicating material delisting risk if the company fails to cure the deficiency.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-03
EX-99.1
Cango announced that it has regained compliance with NYSE's minimum share price requirement (Section 802.01C) after receiving a deficiency notice on March 10, 2026, when its average closing price fell below US$1.00. The company effected a 10-for-1 share consolidation on July 20, 2026, to remedy the violation. The September 1, 2026 NYSE letter confirms the company's average stock price for the 30 trading days ended August 31, 2026 exceeded US$1.00, closing the matter. This disclosure directly addresses a delisting risk that threatened the company's continued listing on NYSE.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-03
Nexentis Technologies received a notice from Nasdaq on August 31, 2026 that its stockholders' equity of $1,782,000 (as of June 30, 2026) falls below the minimum $2,500,000 requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within any extension period granted. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-03
The filing discloses CXApp's regained compliance with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement after receiving a delisting notice on September 11, 2025, and being granted two successive 180-day compliance periods. The company effected a 1-for-50 reverse stock split on August 18, 2026, and subsequently demonstrated 10 consecutive business days at or above $1.00 per share, allowing Nasdaq to confirm closure of the delisting matter. This is a material event as it resolves a substantial going-concern threat to the company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-09-02
Item 8.01
The filing discloses a delisting notice from Nasdaq on July 20, 2026, for failure to maintain the minimum $1.00 bid price requirement under Listing Rule 5550(a)(2). Although the Company subsequently regained compliance on September 2, 2026, the initial non-compliance and delisting risk notification is a material event that would affect investor assessment of the registrant's listing status and market viability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-02
Item 3.01
TScan received written notice from Nasdaq on August 27, 2026, that its common stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), with an initial 180-day compliance period until February 23, 2027.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-02
Item 8.01
The filing discloses CalciMedica's status regarding Nasdaq listing compliance. While the Company resolved one deficiency (market value of listed securities below $35 million minimum), it remains non-compliant with the Minimum Bid Price Requirement (stock below $1.00 per share) with a September 14, 2026 deadline to regain compliance. The disclosure explicitly states "There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with the other listing requirements," indicating material delisting risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-02
Item 3.01
IRIDEX received a formal Notice of Non-Compliance from Nasdaq on August 27, 2026, for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until February 23, 2027) to regain compliance, with potential delisting if it fails to do so. This is a textbook delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued market access and trading status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-02
Item 3.01
Eureka Acquisition Corp received written notice from Nasdaq on August 27, 2026 that it failed to meet two continued listing requirements: (1) the minimum 500,000 publicly held shares under Nasdaq Rule 5550(a)(4), and (2) the $35 million minimum market value of listed securities under Rule 5550(b)(2). While the notices are currently non-binding notifications of deficiency rather than imminent delisting orders, they establish a clear delisting risk with defined compliance periods (45 days for the public float rule and 180 days for the MVLS rule). The disclosure explicitly states "there can be no assurance that the Company will be able to regain or maintain compliance with the MVLS Rule," indicating material uncertainty about the company's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-02
EX-99.1
Scage Future received two Nasdaq deficiency notifications on August 27, 2026, advising that the Company no longer meets minimum Market Value of Listed Securities (MVLS) of $50 million and Market Value of Publicly Held Shares (MVPHS) of $15 million. The Company has been granted a 180-day compliance period through February 23, 2027, and faces potential delisting if it fails to regain compliance. The press release explicitly states that if compliance is not achieved, "the Company will receive written notification that its securities are subject to delisting," and notes that a deficiency indicator will be displayed on Nasdaq. This is a clear delisting-risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-02
BTC Digital received a Nasdaq deficiency letter on August 27, 2026, for non-compliance with the Nasdaq Bid Price Rule (Rule 5550(a)(2)) due to closing bid prices below $1.00 for 30 consecutive business days. The company has been granted a 180-day compliance period until February 23, 2027, with explicit notice that failure to regain compliance could result in delisting. This is a material disclosure of delisting risk under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-02
Item 3.01
Reborn Coffee received a notice from Nasdaq on August 27, 2026, stating that the Company no longer complies with Listing Rule 5250(c)(1) due to failure to file its Form 10-Q for the period ended June 30, 2026. The Company has 60 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within 180 days.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-02
Item 3.01
Triller Group received notice from Nasdaq on August 27, 2026, that it failed to maintain the minimum market value of listed securities (MVLS) of $35 million required under Nasdaq Listing Rule 5550(b)(2), creating a deficiency that "could result in the delisting of the Company's securities from Nasdaq." The company has seven calendar days to submit a compliance plan. This is a textbook delisting-risk disclosure under Item 3.01, and the filing explicitly states the company no longer satisfies a continued listing requirement.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-02
Item 3.01
VenHub Global received formal notification from Nasdaq on September 1, 2026, that it has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days under Nasdaq Marketplace Rule 5450(a)(1). The company has 180 calendar days until March 1, 2027, to regain compliance or faces potential delisting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-02
Item 8.01
The filing discloses that Edible Garden regained compliance with Nasdaq's minimum bid price rule ($1.00 per share) following a July 27, 2026 Hearings Panel decision, but remains subject to a mandatory one-year Panel Monitor through August 31, 2027. Critically, the disclosure explicitly states that any future non-compliance during the monitoring period will result in immediate delisting without opportunity for additional cure periods or compliance plans. The Nasdaq Hearing Panel also maintains jurisdiction through November 23, 2026, with authority to immediately delist if the company fails to maintain the bid price rule. This is a material delisting-risk disclosure under Item 8.01, as it describes the company's precarious listing status and the heightened consequences of future non-compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-02
The filing discloses a written notice from Nasdaq on August 27, 2026, indicating that ARC Group's warrants failed to comply with Nasdaq Listing Rule 5452(b)(C) because the aggregate market value of outstanding warrants fell below the required $1 million minimum. The company has 45 days to submit a compliance plan and up to 180 days to regain compliance, with explicit acknowledgment that failure to do so could result in delisting notice. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-09-02
Item 3.01
The Company notified Nasdaq on August 28, 2026 of non-compliance with Nasdaq Listing Rule 5605(c)(2) due to insufficient Audit Committee members following Mr. Yuji Ishida's resignation. Although the Company subsequently regained compliance by August 31, 2026 through Mr. Kevin Cheong Jia Jin's appointment and Nasdaq confirmed closure of the matter on September 1, 2026, the Item 3.01 disclosure itself documents a material delisting risk event—the triggering non-compliance with a continued listing standard. This is material to investors as it represents a temporary but real threat to the Company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-02
Item 3.01
Senti Biosciences received formal notice from Nasdaq on August 27, 2026 of non-compliance with the Minimum Bid Price Requirement (stock closing below $1.00 for 30 consecutive trading days) and the Stockholders' Equity Requirement (stockholders' deficit of $3.4 million versus $2.5 million minimum), with 180-day compliance periods granted but potential delisting if deficiencies are not cured.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-02
Item 8.01
The disclosure centers on Anavex's regaining compliance with Nasdaq Listing Rule 5250(c)(1) after receiving a delinquency notification for failure to timely file required periodic reports (Form 10-Q). While the filing announces resolution of the compliance issue, the underlying event—the company's prior non-compliance and delisting risk—is material to investors. The company explicitly references the delinquency notification and its plan to regain compliance, confirming this was a delisting-risk situation that has now been remedied.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-09-02
EX-99.1
The exhibit announces that a trading halt imposed on Scorpio Gold's common shares and ADSs earlier that day was done in error, and the Company has requested trading resume. While the halt itself was erroneous and being corrected, any trading halt—even if reversed—signals potential delisting risk or exchange compliance concerns. The disclosure of the halt and request for resumption would affect a reasonable investor's assessment of the Company's listing status and regulatory standing, though the material impact is mitigated by the prompt correction and resumption request.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-02
Item 8.01
Nerdy regained compliance with NYSE Section 802.01C minimum share price requirement after previously falling below the $1.00 threshold. While the disclosure announces resolution of a delisting risk rather than the risk itself, the materiality lies in the prior non-compliance and the company's restoration of listing status. This is material to investors as it directly affects the continued trading of the company's securities on the NYSE.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-01
EX-99.1
Zentek announces that its Nasdaq Capital Market listing has been delisted and trading will be suspended on September 2, 2026, with common shares transitioning to the OTCQX Best Market under ticker ZTEKF. The company states it "intends to request a hearing to appeal the Nasdaq delisting determination," confirming a delisting event. This is a material disclosure under Item 3.01 (Delisting or Transfer of Listing) as it represents a significant change in the registrant's trading venue and liquidity profile, though the company notes the TSX Venture Exchange listing remains unaffected.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-01
Item 3.01
BioXcel was notified by Nasdaq on August 31, 2026, that its common stock would be delisted in accordance with Nasdaq Listing Rules as a result of the Company's Chapter 11 bankruptcy filing on August 27, 2026, with trading to be suspended on September 8, 2026, and the stock expected to move to the OTC Pink Limited Market.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-01
EX-99.1
The exhibit discloses that Nasdaq has granted Alpha Compute an additional 180-day compliance period (until March 1, 2027) to regain compliance with the minimum bid price requirement of $1.00 per share. The company was previously notified on March 2, 2026 that its stock had traded below $1.00 for 30 consecutive business days. This is a material delisting risk disclosure under Item 3.01 equivalent, as the company faces potential delisting if it fails to achieve the required minimum bid price during the compliance period.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-01
EX-99.1
Quantum BioPharma announces a voluntary delisting of its Class B shares from the Canadian Securities Exchange (CSE), effective September 4, 2026. While characterized as voluntary and intended to consolidate trading on Nasdaq, this is a material change in listing status that affects shareholder trading options, liquidity, and market access. The disclosure explicitly identifies risks including reduced trading volume, liquidity, and analyst coverage, as well as potential impacts on resale exemptions and the company's ability to complete private placements—all factors a reasonable investor would consider when assessing the registrant's capital-raising ability and share liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-01
Item 3.03
NYSE American suspended trading of the Company's common stock on July 17, 2026, due to failure to meet the minimum trading price requirement of $0.10 and commenced delisting proceedings. Although the Company implemented a 1-for-40 reverse stock split to attempt compliance, there is no assurance that the delisting determination will be reversed, and failure to resume NYSE American trading would result in continued OTC trading with negative impacts on liquidity and financing ability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-09-01
Item 3.01
XTI Aerospace received a Nasdaq deficiency notice on August 26, 2026, for failure to timely file its Form 10-Q for Q2 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan or faces potential delisting, with no assurance it will regain or maintain compliance with Nasdaq's continued listing requirements.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-01
The filing discloses receipt of a notice from Nasdaq on August 26, 2026, stating that Borealis Foods no longer complies with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Q2-2026 Form 10-Q. While the notice has no immediate effect on listing, the company has until October 26, 2026 to submit a compliance plan and until February 16, 2027 to regain compliance, creating a material delisting risk under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-09-01
EX-99.1
CollPlant announces a one-for-ten reverse share split explicitly "being implemented as part of the Company's strategic plan to regain compliance with the Nasdaq minimum bid price requirement for continued listing." This is a direct response to delisting risk — the company is taking corrective action to avoid loss of listing status. While the reverse split itself is a capital structure event, the disclosure's material substance is the underlying delisting threat and the company's remedial measure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-09-01
Item 3.01
CID HoldCo received a third delisting notice from Nasdaq on August 27, 2026, citing failure to file its Form 10-Q for the period ended June 30, 2026, in addition to prior determinations for failure to meet minimum market value requirements. The company's common stock remains listed pending a Nasdaq Hearings Panel decision but faces imminent delisting risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-01
Item 3.01
authID Inc. received a deficiency notice from Nasdaq on August 27, 2026, for failing to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, triggering a 180-day compliance period ending February 23, 2027. The filing explicitly discloses the delisting risk under Item 3.01, noting that failure to regain compliance could result in delisting and that the company also faces a separate stockholders' equity deficiency that could preclude eligibility for a second compliance period. This is a material disclosure of delisting risk that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-09-01
Item 8.01
The Company discloses delinquent quarterly filings (10-Qs for Q1 and Q2 2026) and a late annual filing (2025 10-K filed after deadline), with failure to file timely Form 12b-25 notifications. These reporting delinquencies create material delisting risk under exchange continued listing standards, which typically require timely periodic report filings. While the disclosure does not explicitly mention delisting notice, the pattern of missed deadlines and acknowledged non-compliance with SEC filing obligations directly threatens the Company's exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-01
The filing discloses a conditional decision by the Nasdaq Hearings Panel granting continued listing of Snail's Class A Common Stock on the Nasdaq Capital Market, contingent on achieving minimum stockholders' equity of $2,500,000 under Nasdaq Listing Rule 5550(b). The filing explicitly states "There can be no assurance that the Company will satisfy the conditions of the Panel's decision or otherwise regain compliance with the applicable listing requirements, and a failure to do so would result in the delisting of the Company's securities from Nasdaq." This is a material delisting risk disclosure under Item 3.01 (or Item 8.01 as presented here).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-01
The filing discloses that U.S. GoldMining received written notice from Nasdaq on August 27, 2026, stating the Company no longer complies with Nasdaq Listing Rule 5605 (audit committee requirements) following a director's resignation. Although Nasdaq granted a cure period until the earlier of the next annual shareholders' meeting or August 14, 2027, the Company faces delisting risk if it fails to regain compliance. This is a material disclosure under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-01
Item 8.01
The filing discloses that Beyond Meat received a deficiency letter on March 4, 2026 for failing to maintain the Nasdaq minimum bid price requirement of $1.00 per share, was given 180 days to regain compliance, and subsequently regained compliance on August 28, 2026. This is a classic delisting-risk disclosure under Item 8.01 — the company faced a material threat of delisting but has now cured the deficiency. The explicit reference to Nasdaq Listing Rule 5450(a)(1) and the compliance determination confirms this classification.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-01
EX-99.1
The press release announces NuRAN Wireless's application for voluntary delisting from the Canadian Securities Exchange (CSE), with September 4, 2026 expected as the final trading day on that exchange. While the company states this is a voluntary action to consolidate trading on NASDAQ and reduce dual-listing costs, the delisting itself is a material change in listing status that affects investor access and trading venues. The disclosure also includes a director resignation (Navindran Naidoo), but the primary event disclosed is the delisting action.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-01
Item 3.01
IP Strategy Holdings received a Nasdaq notification on August 26, 2026, for failure to timely file its Form 10-Q for the period ended June 30, 2026, placing it in non-compliance with Nasdaq Listing Rule 5250(c)(1). The filing explicitly states that "if the Company fails to timely regain compliance with the Listing Rule 5250(c)(1), the Company's common stock will be subject to delisting from Nasdaq." This is a classic delisting-risk disclosure under Item 3.01, with a 60-day cure period ending October 26, 2026, and potential 180-day extension to February 22, 2027.
View raw filing on EDGAR →